High-carbohydrate high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 1, 2011, Pages 51-64

  Panchal, Sunil K ^a   Poudyal, Hemant ^b   Iyer, Abishek ^b   Nazer, Reeza ^b   Alam, Ashraful ^b   Diwan, Vishal ^b   Kauter, Kathleen ^a   Sernia, Conrad ^b   Campbell, Fiona ^b   Ward, Leigh ^b   Gobe, Glenda ^b   Fenning, Andrew ^c   Brown, Lindsay ^a,b  

^a UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c CENTRAL QUEENSLAND UNIVERSITY   (Australia)

Author keywords

cardiovascular disease; dyslipidemia; high carbohydrate; high fat diet; hypertension; Metabolic syndrome; obesity

Indexed keywords

CARBOHYDRATE; DRINKING WATER; FRUCTOSE; GLUCOSE; LEPTIN; LIPID; LIVER ENZYME; MALONALDEHYDE; STARCH; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM ION; CHLORIDE ION; CHOLESTEROL; CORTICOSTERONE; CREATININE; FATTY ACID; GLOBULIN; INSULIN; LACTATE DEHYDROGENASE; POTASSIUM ION; REACTIVE OXYGEN METABOLITE; SODIUM ION; SUPEROXIDE; TRIACYLGLYCEROL; UREA; URIC ACID; WATER;

ABDOMINAL OBESITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHROPOMETRY; ARTICLE; CALORIC INTAKE; CARBOHYDRATE DIET; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HEART REPOLARIZATION; HYPERINSULINEMIA; HYPERTROPHY; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; KIDNEY FUNCTION; LIPID DIET; LIVER FIBROSIS; LIVER FUNCTION; LIVER WEIGHT; MALE; METABOLIC SYNDROME X; MILK; NONHUMAN; OBESITY; PANCREAS FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN; ABDOMINAL FAT DEPOSITION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL TISSUE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEEF TALLOW; BLOOD LEVEL; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONDENSED MILK; ERYTHROCYTE; FIBROSIS; FLUID INTAKE; FOOD INTAKE; HEART; HEART FUNCTION; HEART LEFT VENTRICLE; HISTOLOGY; KIDNEY; LIPID STORAGE; LIVER; PANCREAS; REPOLARIZATION; RIGIDITY;

ABDOMINAL FAT; ANIMALS; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIETARY CARBOHYDRATES; DIETARY FATS; ENERGY INTAKE; FRUCTOSE; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LEPTIN; LIVER; MALE; METABOLIC SYNDROME X; OBESITY; RANDOM ALLOCATION; RATS; RATS, WISTAR; VENTRICULAR REMODELING; BIOLOGICAL MARKERS; BLOOD PRESSURE; ERYTHROCYTES; KIDNEY; OXIDATIVE STRESS; PANCREAS; REACTIVE OXYGEN SPECIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79957796961     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181feb90a     Document Type: Article

References (79)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787.
2. Hunt KJ, Resendez RG,Williams K, et al. National Cholesterol Education Program versus World Health Organization. Metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251-1257.
3. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
4. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
5. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419.
6. Grundy SM. A constellation of complications: the metabolic syndrome. Clin Cornerstone. 2005;7:36-45.
7. Magliano DJ, Shaw JE, Zimmet PZ. How to best define the metabolic syndrome. Ann Med. 2006;38:34-41.
8. Roberts CK, Barnard RJ, Sindhu RK, et al. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in dietinduced metabolic syndrome. Metabolism. 2006;55:928-934.
9. Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-1454.
10. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875-880.
11. Tarquini R, Lazzeri C, Pala L, et al. The diabetic cardiomyopathy [published online ahead of print March 3, 2010]. Acta Diabetol. doi: 10.1007/s00592-010-0180-x.
12. Iyer A, Fairlie DP, Prins JB, et al. Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol. 2010;6:71-82.
13. Wang CY, Chau LY. Heme oxygenase-1 in cardiovascular diseases: molecular mechanisms and clinical perspectives. Chang Gung Med J. 2010;33:13-24.
14. Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab. 2005;7:307-317.
15. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res. 1998;39:89-105.
16. Flamment M, Arvier M, Gallois Y, et al. Fatty liver and insulin resistance in obese Zucker rats: no role for mitochondrial dysfunction. Biochimie. 2008;90:1407-1413.
17. Liu RH, Mizuta M, Kurose T, et al. Early events involved in the development of insulin resistance in Zucker fatty rat. Int J Obes Relat Metab Disord. 2002;26:318-326.
18. Bitar MS, Al-Saleh E, Al-Mulla F. Oxidative stress-mediated alterations in glucose dynamics in a genetic animal model of type II diabetes. Life Sci. 2005;77:2552-2573.
19. Cacanyiova S, Kristek F. Adaptive vasoactive response to modulatory effects of endothelin-1 in spontaneously hypertensive rats. Pharmacol Rep. 2008;60:941-949.
20. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000;101:899-907.
21. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008;51:216-226.
22. Marsh SA, Dellitalia LJ, Chatham JC. Interaction of diet and diabetes on cardiovascular function in rats. Am J Physiol Heart Circ Physiol. 2009; 296:H282-H292.
23. Pang X, Zhao J, Zhang W, et al. Antihypertensive effect of total flavones extracted from seed residues of Hippophae rhamnoides L. in sucrose-fed rats. J Ethnopharmacol. 2008;117:325-331.
24. Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high fructose-fed rats. J Comp Physiol B. 2004;174:587-592.
25. Buettner R, Parhofer KG, Woenckhaus M, et al. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol. 2006;36:485-501.
26. Reil TD, Barnard RJ, Kashyap VS, et al. Diet-induced changes in endothelial-dependent relaxation of the rat aorta. J Surg Res. 1999;85: 96-100.
27. Schaalan M, El-Abhar HS, Barakat M, et al. Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride. J Diabetes Complications. 2009;23:199-208.
28. Hubbell RB, Mendel LB, Wakeman AJ. A new salt mixture for use in experimental diets. J Nutr. 1937;14:273-285.
29. Novelli EL, Souza GA, Ebaid GM, et al. Energy expenditure and oxygen consumption as novel biomarkers of obesity-induced cardiac disease in rats. Obesity (Silver Spring). 2010;18:1754-1761.
30. Ward LC, Battersby KJ. Assessment of body composition of rats by bioimpedance spectroscopy validation against dual-energy x-ray absorptiometry. Scand J Lab Anim Sci. 2009;36:253-261.
31. Brown L, Fenning A, Chan V, et al. Echocardiographic assessment of cardiac structure and function in rats. Heart Lung Circ. 2002;11:167-173.
32. Sahn DJ, Allen HD. Real-time cross-sectional echocardiographic imaging and measurement of the patent ductus arteriosus in infants and children. Circulation. 1978;58:343-354.
33. Litwin SE, Katz SE, Morgan JP, et al. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994;89:345-354.
34. Allan A, Fenning A, Levick S, et al. Reversal of cardiac dysfunction by selective ET-A receptor antagonism. Br J Pharmacol. 2005;146:846-853.
35. Chan V, Hoey A, Brown L. Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats. Br J Pharmacol. 2006; 148:902-908.
36. Fenning A, Harrison G, Rosemeyer R, et al. L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol. 2005;289:H1408-H1416.
37. Wang H, Joseph JA. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med. 1999;27: 612-616.
38. Sim AS, Salonikas C, Naidoo D, et al. Improved method for plasma malondialdehyde measurement by high-performance liquid chromatography using methyl malondialdehyde as an internal standard. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;785:337-344.
39. Muntner P, He J, Chen J, et al. Prevalence of non-traditional ardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 2004;14:686-695.
40. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev. 2010;11:430-445.
41. Zhang G, Hamaker BR. Slowly digestible starch: concept, mechanism, and proposed extended glycemic index. Crit Rev Food Sci Nutr. 2009;49: 852-867.
42. Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high fructose-fed rats. J Comp Physiol B. 2004;174:587-592.
43. Patel J, Iyer A, Brown L. Evaluation of the chronic complications of diabetes in a high fructose diet in rats. Indian J Biochem Biophys. 2009; 46:66-72.
44. Martin B, Ji S, Maudsley S, et al. Control laboratory rodents are metabolically morbid: why it matters. Proc Natl Acad Sci U S A. 2010; 107:6127-6133.
45. Jo J, Gavrilova O, Pack S, et al. Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLoS Comput Biol. 2009;5:e1000324.
46. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314: 1-16.
47. Fam BC, Morris MJ, Hansen MJ, et al. Modulation of central leptin sensitivity and energy balance in a rat model of diet-induced obesity. Diabetes Obes Metab. 2007;9:840-852.
48. Ryan AS, Bailey-Hall E, Nelson EB, et al. The hypolipidemic effect of an ethyl ester of algal-docosahexaenoic acid in rats fed a high-fructose diet. Lipids. 2009;44:817-826.
49. Van Guilder GP, Hoetzer GL, Greiner JJ, et al. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring). 2006;14:2127-2131.
50. Athyros VG, Tziomalos K, Karagiannis A, et al. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets. 2010;11:122-135.
51. Ritchie RH. Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. Heart Lung Circ. 2009; 18:11-18.
52. Delles C, Zimmerli LU, McGrane DJ, et al. Vascular stiffness is related to superoxide generation in the vessel wall. J Hypertens. 2008;26:946-955.
53. Matsuzawa-Nagata N, Takamura T, Ando H, et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism. 2008;57:1071-1077.
54. Lamb RE, Goldstein BJ. Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract. 2008;62: 1087-1095.
55. Liu C, Cao F, Tang QZ, et al. Allicin protects against cardiac hypertrophy and fibrosis via attenuating reactive oxygen species-dependent signaling pathways. J Nutr Biochem. 2010;21:1238-1250.
56. Kourie JI. Interaction of reactive oxygen species with ion transport mechanisms. Am J Physiol. 1998;275(1 pt 1):C1-C24.
57. Tabet F, Savoia C, Schiffrin EL, et al. Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2004;44: 200-208.
58. Guerra L, Cerbai E, Gessi S, et al. The effect of oxygen free radicals on calcium current and dihydropyridine binding sites in guinea-pig ventricular myocytes. Br J Pharmacol. 1996;118:1278-1284.
59. 2+]i in canine cerebral arterial smooth muscle: participation of cellular signaling pathways. Naunyn Schmiedebergs Arch Pharmacol. 1999;360:646-653.
60. Yang ZW, Zheng T, Zhang A, et al. Mechanisms of hydrogen peroxideinduced contraction of rat aorta. Eur J Pharmacol. 1998;344:169-181.
61. Ermak G, Davies KJ. Calcium and oxidative stress: from cell signaling to cell death. Mol Immunol. 2002;38:713-721.
62. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
63. Doenst T, Pytel G, Schrepper A, et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res. 2010;86: 461-470.
64. Yu M, Liu Y, Xiang F, et al. CHF1/Hey2 promotes physiological hypertrophy in response to pressure overload through selective repression and activation of specific transcriptional pathways. OMICS. 2009;13: 501-511.
65. MacKenna D, Summerour SR, Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res. 2000;46:257-263.
66. Newsholme P, Homem De Bittencourt PI, O Hagan C, et al. xercise and possible molecular mechanisms of protection from vascular disease and diabetes: the central role of ROS and nitric oxide. Clin Sci. 2009;118: 341-349.
67. Cerbai E, Barbieri M, Li Q, et al. Ionic basis of action potential prlongation of hypertrophied cardiac myocytes isolated from hypertensive rats of different ages. Cardiovasc Res. 1994;28:1180-1187.
68. Wei M, Ong L, Smith MT, et al. The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ. 2003; 12:44-50.
69. Qin D, Huang B, Deng L, et al. Downregulation of K(+) channel genes expression in type I diabetic cardiomyopathy. Biochem Biophys Res Commun. 2001;283:549-553.
70. Cerbai E, Crucitti A, Sartiani L, et al. Long-term treatment spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes. Cardiovasc Res. 2000;45: 388-396.
71. Furukawa T, Kurokawa J. Potassium channel remodeling in cardiac hypertrophy. J Mol Cell Cardiol. 2006;41:753-761.
72. Tamargo J, Caballero R, Gomez R, et al. Pharmacology of cardiac potassium channels. Cardiovasc Res. 2004;62:9-33.
73. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15:316-328.
74. Stanhope KL, Havel PJ. Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. Curr Opin Lipidol. 2008;19:16-24.
75. Miller A, Adeli K. Dietary fructose and the metabolic syndrome. Curr Opin Gastroenterol. 2008;24:204-209.
76. Le KA, Tappy L. Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care. 2006;9:469-475.
77. Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320-330.
78. Tozawa M, Iseki C, Tokashiki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res. 2007;30:937-943.
79. Ai J, Wang N, Yang M, et al. Development of Wistar rat model of insulin resistance. World J Gastroenterol. 2005;11:3675-3679.